Blood Preparation Market (2026 - 2033) Size, Share & Trends Analysis Report By Product (Whole Blood, Blood Components, Blood Derivatives), By Antithrombotic And Anticoagulants, By Application, By Region, And Segment Forecasts

Blood Preparation Market Summary

The global blood preparation market size was estimated at USD 53.56 billion in 2025 and is anticipated to reach USD 91.88 billion by 2033, growing at a CAGR of 7.1% from 2026 to 2033. The growing incidence of blood-related disorders, the rising number of transfusion procedures, and the increasing number of donations are the major factors driving the market.

Moreover, extensive usage of blood and its components in several surgical procedures, increasing number of accidents, and growing donations are also expected to fuel the market growth over the study period. For instance, according to the American National Red Cross, in the U.S., approximately 6.8 million people donate blood, and about 13.6 million units of red blood cells and whole blood are collected annually in the U.S. 

The increasing prevalence of blood-related disorders, such as anemia, hemophilia, leukemia, and thrombocytopenia, is a primary driver for the growth of the global blood preparation market. According to the World Health Organization (WHO), it is estimated that anemia affects nearly 1.6 billion people globally, increasing the demand for red blood cell concentrates and iron supplements. Similarly, hemophilia affects approximately 400,000 people worldwide, requiring regular access to plasma-derived products such as clotting factors. In addition, according to a report published by the Institute for Health Metrics and Evaluation (IHME), globally in 2021, 31.2% of women had anemia compared with 17,5% of men, keeping anemia prevalence in women rising over the years. Similarly, abnormal Complete Blood Count (CBC) test results often indicate underlying infections, thereby creating a consistent demand for diagnosis among patient.

On 4 December 2025, Parse Biosciences announced the launch of Evercode Whole Blood Fixation, a solution designed to stabilize whole blood samples immediately after collection for single-cell RNA sequencing applications. The product enables simplified sample handling by eliminating the need for immediate peripheral blood mononuclear cell (PBMC) isolation and specialized processing at collection sites. This development strengthens innovation within the blood sample preparation segment, particularly for genomics research and translational diagnostics, by enabling decentralized and more flexible blood collection workflows.

Transfusions are essential in the treatment of numerous conditions such as anemia, trauma, surgical procedures, and cancer treatments. For instance, in leukemia patients the body’s factory that makes blood damaged, hence transfusion is essential to manage the disease and its symptoms. Moreover, the rising prevalence of chronic diseases and advancements in healthcare technologies have further contributed to the growing demand for products.

In addition, increasing research and development activities on preparation methods is anticipated to propel the market growth during the review period. For instance, in December 2025, authorities in Jamshedpur ordered MGM Medical College’s blood bank to implement ELISA kits for blood screening following the submission of a probe report. The directive reinforces the importance of standardized infectious disease screening protocols in blood banks to ensure transfusion safety. Although not a commercial product launch, the incident highlights the strong regulatory oversight influencing the blood preparation and screening market, driving demand for validated blood testing kits and compliance-focused laboratory practices. Furthermore, launch of new blood bank centers across the globe are likely to offer ample opportunities for the market. For instance, in March 2023, Kenya's Ministry of Health, introduced a satellite blood bank center for improving access to quality and safe transfusion services in the region.

Furthermore, innovations in blood collection and storage technology, including apheresis, have enhanced the ability to efficiently collect specific blood components such as plasma and platelets. This supports the supply chain for advanced preparations such as plasma-derived therapies. In addition, introduction of novel technologies along with the increasing usage of plasma in the pharmaceutical industry is further projected to contribute to market growth over the forecast period. For instance, in April 2021, EryPharm introduced a medical device to manufacture cultured red blood cells in large quantities and create new blood sources for transfusions. Various governments across the globe are focusing on increasing the number of donations by applying reimbursement policies, such as monetary incentives for donors. For instance, in September 2021, The American Red Cross introduced a national initiative to reach a maximum number of donors to improve health outcomes in patients with sickle cell disease. This factor is also expected to augment the growth of the global market over the next few years.

Market Concentration & Characteristics

The degree of innovation in the market is high, as companies continuously develop and introduce automated blood separation systems, advanced cell processing technologies, pathogen reduction platforms, and molecular-grade sample preparation solutions to enhance safety, efficiency, and turnaround time in both transfusion and diagnostic applications. Promega Corporation continues to promote its Maxwell RSC Blood DNA Kit, designed for automated genomic DNA extraction from whole blood samples. The kit supports downstream molecular applications such as PCR, sequencing, and genotyping, enabling efficient and standardized blood sample preparation. This product reinforces the expanding role of molecular-grade blood preparation technologies in diagnostics, research, and personalized medicine workflows, contributing to growth in automated nucleic acid extraction solutions within the broader blood preparation market.

The level of mergers and acquisitions (M&A) activities in market is medium. While there have been some strategic acquisitions by major diagnostic companies to strengthen their product portfolios and expand market reach, such as in June 2025, French in-vitro diagnostics leader bioMérieux announced a strategic acquisition of the assets and technologies of Day Zero Diagnostics, a US company developing rapid infectious disease diagnostics. The deal brings into bioMérieux’s R&D pipeline workflows and reagents that include direct-from-whole-blood sample preparation, advanced sequencing and bioinformatics tools designed to identify bacterial pathogens and their antibiotic resistance profiles within hours instead of days. Companies are primarily focusing on organic growth through research and development or partnerships to innovate and capture market share.

The impact of regulation is high, as regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and national blood safety authorities enforce stringent standards for blood collection, processing, storage, traceability, and infectious disease screening, significantly influencing product approvals, compliance costs, and market entry timelines.

Product expansion remains a key growth factor, with manufacturers increasingly launching closed-system processing kits, automated apheresis devices, leukoreduction filters, pathogen inactivation technologies, and integrated blood preparation platforms tailored for hospitals, blood banks, and advanced diagnostic laboratories.

Regional expansion is accelerating as emerging economies invest in modern blood banking infrastructure, strengthen transfusion safety programs, expand diagnostic capabilities, and adopt automation technologies to meet rising surgical volumes, trauma cases, and the growing burden of hematological and infectious diseases.

Product Insights

The whole blood product segment held the largest revenue share at 45.51% in 2025. The segment growth is majorly attributed to an increasing demand for major surgeries and transfusions along with its advantages, such as easy availability, low cost, and maintenance, is the major factor contributing to the segment’s high share. For instance, in December 2024, Haemonetics Corporation announced the sale of its whole blood collection, processing, and filtration product portfolio to GVS S.p.A for total consideration of up to approximately USD 67 million. The transaction includes associated manufacturing facilities in the United States and Mexico. This strategic divestment allows Haemonetics to streamline its portfolio and focus on higher-growth areas, while strengthening GVS’s presence in transfusion medicine and blood processing technologies. The deal directly impacts the whole blood preparation segment by shifting ownership of blood collection and filtration assets, thereby altering competitive positioning within the blood component processing market.

The blood derivatives segment is expected to exhibit the considerable growth in the market over the forecast period. Implementing government initiatives to develop plasma-derived proteins, such as immunoglobulins, coagulation factor products, human fibrin foam, dried human plasma, and human thrombin, are expected to drive the segment growth. For instance, in August 2022, the Human and Health Services Department launched a new campaign with a focus on increasing blood and plasma donations in the U.S.

Antithrombotic and Anticoagulants Insights

The anticoagulants segment held the largest revenue share at 65.00% in 2025, attributed to the introduction of new products and the increasing prevalence of cardiac conditions. With ongoing research and development activities, the anticoagulants market is expected to grow substantially in the coming years, offering improved therapeutic options for patients at risk of clotting disorders. For instance, in May 2023, Endo executed agreements with Gland Pharma Limited and MAIA Pharmaceuticals, Inc. to commercialize bivalirudin anticoagulant (thrombin inhibitor) that helps prevent the formation of clots in the U.S. market.

The fibrinolytic segment is expected to exhibit the fastest growth over the forecast period. Biopharmaceutical companies are upgrading their products by launching novel and more efficient anticoagulant drugs in the market. Moreover, strategic programs conducted by market players are further projected to fuel the segment growth during the forecast period. For instance, in February 2023, Janssen Pharmaceuticals, Inc. and Bristol Myers Squibb entered into a strategic collaboration and launched a pivotal phase 3 Librexia clinical trial program.

Application Insights

The thrombocytosis segment captured the largest revenue share at 21.40% in 2025. Increasing prevalence of thrombocytosis, growing awareness and diagnosis of the condition, and advancements in diagnostic techniques are substantially playing a role in maximum segment share. Additionally, the development of targeted therapies and novel treatment options for thrombocytosis is further expected to fuel market growth. 

The angina blood vessel is expected to exhibit the fastest growth in the market over the forecast period. Certain factors such as rising R&D for the development of anticoagulants for cardiac problems and increasing prevalence of Cardiovascular Disorders (CVDs) are estimated to drive the segment growth. Furthermore, a rise in lifestyle-associated diseases, the popularity of oral anticoagulants, growing patient awareness, increased healthcare expenditure, and favorable government policies are the factors driving the segment.

Regional Insights

North America blood preparation market dominated and accounted for a 43.71% share in 2025. owing to the high incidence of CVDs, leukemia, and hematological and neurological diseases in the region. For instance, according to the American Cancer Society’s estimates for 2023 in the U.S., approximately 59,610 new cases of leukemia and 23,710 deaths from leukemia. Higher patient awareness and healthcare expenditure levels along with the presence of sophisticated healthcare infrastructure likely to boost the region’s growth further.

U.S. Blood Preparation Market Trends

The blood preparation market in U.S. is projected to grow significantly during the forecast period, driven by the According to a recent report by Leukemia and Lymphoma Society, in 2023, an estimated 184,720 people in the U.S. are expected to be diagnosed with leukemia, lymphoma, or myeloma. Most cases of leukemia occur in older adults, the median age at diagnosis is 67 years. The growing prevalence of blood illness amongst the population is rising demand for hematology diagnostic test kits and equipment. For instance, according to the American Society of Hematology, Sickle cell trait, a blood disorder, affects 1 million to 3 million Americans, and more than 100 million people worldwide carry the sickle cell trait. The presence of several pharmaceutical and medical device companies is further driving market growth in the country.

Europe Blood Preparation Market Trends

The blood preparation market in Europe is likely to emerge as a lucrative region in the industry, driven by advanced healthcare infrastructure, increasing awareness of blood-related disorders, and robust transfusion networks. Favorable government policies and investments in research for innovative products further bolster the market. Competitive dynamics involve key players such as Grifols, Sanquin, and CSL Behring, leveraging technological advancements and partnerships to enhance product availability across European countries.

Theblood preparation market in UKis projected to grow during the forecast period, fueled by the country’s focus on improving transfusion services, rising donations, and increasing prevalence of hematological disorders. Government-backed initiatives such as “The NHS Blood and Transplant campaign” for self-sufficiency in blood supply and innovation in plasma-derived therapies enhance market competitiveness. Major players such as NHS Blood and Transplant actively collaborate with private entities to meet rising demands. For instance, in November 2023, The NHS's recent success in saving thousands of lives through the rapid rollout of blood thinners highlights the critical role of anticoagulants in modern healthcare. This initiative highlights the growing demand for thinners like warfarin, heparin, and direct oral anticoagulants, driven by their effectiveness in preventing strokes and other complications. The program exemplifies how government-led healthcare strategies can significantly boost the adoption of life-saving blood preparation products, influencing market growth.

France blood preparation marketis expected to show steady growth over the forecast period, driven by increasing transfusion procedures and an efficient national blood donation system. The French government's investments in advanced storage and transfusion technologies further aid market expansion. Companies like LFB Group play a vital role in maintaining a competitive edge through product innovation and export-oriented strategies.

The blood preparation market in Germanyis projected to expand during the forecast period, driven by a high prevalence of blood-related disorders and a well-established donation and transfusion network. Research advancements and collaborations between industry players and healthcare institutions boost competitiveness. Companies such as Octapharma and CSL Behring dominate the market with a focus on innovation and quality standards.

Asia Pacific Blood Preparation Market Trends

The blood preparation market in Asia Pacificis expected to experience the fastest growth rate during the forecast period, driven by increasing healthcare expenditure, rising prevalence of anemia and leukemia, and growing public awareness. Competitive dynamics are shaped by regional players expanding their presence, while international firms such as Baxter International invest in local manufacturing and distribution networks.

The blood preparation market in Chinais projected to expand throughout the forecast period, driven by several key factors, including increasing number of transfusion procedures, advancements in healthcare infrastructure, and supportive government policies. Partnerships between international and local manufacturers, such as Grifols and Sinopharm, enhance the market's competitive landscape, focusing on accessibility and affordability. For instance, in March 2020, Shanghai RAAS acquired a non-majority stake in Grifols Diagnostic Solutions. This alliance aims at enhancing the production and distribution of plasma-derived therapies and transfusion diagnostics in China, adhering to global quality standards.

Theblood preparation market Japanis anticipated to grow during the forecast period, supported by an aging population and high healthcare standards. The government’s initiatives to streamline blood donation and improve transfusion safety further propel the market. Competitive dynamics involve domestic players such as Japan Red Cross Society, working alongside global leaders to ensure a stable blood supply.

Latin America Blood Preparation Market Trends

The blood preparation market in Latin Americais expected to experience significant growth throughout the forecast period. The market is driven by rising awareness, increasing donations, and a growing prevalence of blood disorders. Competitive dynamics include regional collaborations, with companies like Biotoscana and international firms investing in improving blood banking systems.

Theblood preparation market in Brazilis anticipated to grow during the forecast period. The growth is fueled by government campaigns promoting voluntary donations and improving healthcare access. Companies such as Hemobrás and Grifols enhance market competitiveness through public-private partnerships and localized production. Furthermore, if approved, the trade would allow for the commercialization of human plasma, expanding opportunities for plasma-derived therapies. This move aims to address domestic healthcare needs, reduce reliance on imports, and align with global practices. The change could attract investments from pharmaceutical companies and enhance Brazil's self-sufficiency in plasma products, benefiting both patients and the healthcare sector.

Middle East and Africa Blood Preparation Market Trends

The MEA blood preparation market is expanding as awareness of blood-related diseases rises q across the region. Initiatives to improve healthcare access, especially in underserved areas, have enhanced the adoption of testing kits. Moreover, the growing affordability of these solutions and the rising efforts to increase patient comfort further contribute to this growth.

The blood preparation market in Saudi Arabiais anticipated to experience substantial growth during the forecast period, driven by government investments in healthcare modernization, rising transfusion requirements, and increasing donations. Competitive efforts involve major healthcare providers and international manufacturers addressing rising demands through innovative products and services.

Key Blood Preparation Company Insights

The global blood preparation industry is highly competitive, with numerous players striving to maintain market leadership through innovation, product diversification, and strategic investments. These companies boast extensive product portfolios, a broad geographic presence, and robust distribution networks, allowing them to cater to a wide range of customer needs across both clinical and direct-to-consumer markets. To stay ahead of the competition, many industry leaders have made substantial investments in research and development, enabling them to introduce advanced and cutting-edge blood preparation solutions. Key market players operating in this market are entering into several strategic collaborations and partnerships to expand their existing diagnostics and collection product portfolio. For instance, in May 2023, Bayer received U.S. FDA fast track designation for asundexian which is currently undergoing Phase III OCEANIC clinical trial program. The drug is a novel alternative treatment for thrombosis management with the goal to uncouple efficacy form increased bleeding risk.

Recent Developments

• In June 2025, French in-vitro diagnostics leader bioMérieux announced a strategic acquisition of the assets and technologies of Day Zero Diagnostics, a US company developing rapid infectious disease diagnostics. The deal brings into bioMérieux’s R&D pipeline workflows and reagents that include direct-from-whole-blood sample preparation, advanced sequencing and bioinformatics tools designed to identify bacterial pathogens and their antibiotic resistance profiles within hours instead of days.

• In October 2024, Accelerate Diagnostics received FDA 510(k) clearance for its Accelerate Arc System, a blood culture sample preparation platform. The system streamlines the preparation of positive blood culture samples, enabling faster identification of pathogens and aiding sepsis treatment. It integrates with Bruker’s MALDI Biotyper CA system for direct microbial identification, eliminating the need for labor-intensive traditional methods and overnight cultures.

• In May 2023, Bayer received U.S. FDA fast track designation for asundexian which is currently undergoing Phase III OCEANIC clinical trial program. The drug is a novel alternative treatment for thrombosis management with the goal to uncouple efficacy form increased bleeding risk.

• In May 2023, Endo executed agreements with Gland Pharma Limited and MAIA Pharmaceuticals, Inc. to commercialize bivalirudin anticoagulant (thrombin inhibitor) that prevents the formation of clots in the U.S. market.

• In February 2023, Janssen Pharmaceuticals, Inc. and Bristol Myers Squibb entered into strategic collaboration and launched pivotal phase 3 Librexia clinical trial program.

Blood Preparation Market Report Scope

Global Blood Preparation Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global blood preparation market report based on product, antithrombotic & anticoagulants, application, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Whole Blood

    • Red Cells

    • Granulocytes

    • Plasma

    • Platelets

  • Blood Components

    • Whole Blood Components

    • Packed Red Cells

    • Leukocyte Reduced Red Blood Cells

    • Frozen Plasma

    • Platelet Concentrate

    • Cryoprecipitate

  • Blood Derivatives

• Antithrombotic and Anticoagulants Outlook (Revenue, USD Million, 2021 - 2033)

  • Platelet Aggregation Inhibitors

    • Glycoprotein Inhibitors

    • COX Inhibitors

    • ADP Antagonists

    • Others

  • Fibrinolytics

    • Tissue Plasminogen Activator (tPA)

    • Streptokinase

    • Urokinase

  • Anticoagulants

    • Heparins

      • Unfractionated Heparin

      • Low Molecular Weight Heparin (LMWH)

      • Ultra-low Molecular Weight Heparin

    • Vitamin K Antagonists

    • Direct Thrombin Inhibitors

    • Direct Factor Xa Inhibitors

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Thrombocytosis

  • Pulmonary Embolism

  • Renal Impairment

  • Angina Blood Vessel Complications

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait